Monika Kowalczyk

Monika Kowalczyk, MD PhD has extensive work experience in various positions and organizations. Monika is currently working at Decibel Therapeutics as the Head of Systems Biology, a role they have held since January 2023. Prior to this, they served as the Director and Associate Director of Systems Biology at the same company from December 2020 to January 2023 and from June 2019 to December 2020, respectively.

Before joining Decibel Therapeutics, Kowalczyk worked as a Principal Scientist at Celsius Therapeutics from January 2018 to June 2019. Monika was also a Consultant at Third Rock Ventures, a Venture Capital firm, from 2017 to 2018, focusing on building and launching transformative life science companies.

Kowalczyk's earlier experience includes roles as a Visiting Scientist, Senior Research Fellow, and Postdoctoral Fellow/Broad Fellow at the Broad Institute of MIT and Harvard. During this time, they conducted research and published several scientific papers on topics related to cellular taxonomy, hematopoiesis, and the function of mammalian cells.

Additionally, they worked as a Consultant at Deerfield Management, an investment management firm focused on healthcare, from 2016 to 2017. Kowalczyk also served as a Postdoctoral Fellow at Brigham and Women's Hospital, where they conducted research on circadian clock genes and their regulation of leukemia stem cells.

Prior to their postdoctoral positions, they were a Postdoctoral Fellow and Visiting Scholar at the University of Oxford, where they focused on molecular biology and chromatin signatures.

Overall, Monika Kowalczyk has a diverse background in systems biology, genomics, and molecular biology, with a strong focus on applying their expertise to advance healthcare and make a difference in patients' lives.

Monika Kowalczyk, MD PhD has an extensive education history. Monika obtained their Doctor of Medicine (MD) degree in Hematology from the Medical University of Lodz, where they studied from 1999 to 2005. Following this, they pursued a Doctor of Philosophy (DPhil) in Molecular Biology/Molecular Medicine at the University of Oxford from 2005 to 2010. Most recently, in 2017, they completed an Executive Education program at Harvard Business School.